|Articles|October 1, 2012

Warning on SimplyThick now includes infants of any age

The US Food and Drug Administration (FDA) cautions that SimplyThick, a brand of thickening agent added to breast milk or formula for premature babies, has been linked to necrotizing enterocolitis (NEC) in a full-term infant.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!

Related Content

EC prescribing has not changed post Dobbs

ByMarian Freedman,Jon Matthew Farber, MD

November 11th 2025

ByHeart Whole Nutrition Infant Formula | Image credit: FDA

FDA, CDC investigating multistate infant botulism outbreak tied to formula

ByJoshua Fitch, Senior Editor

November 11th 2025

Can you diagnose this 18-year-old with nausea and vomiting?

ByAbigail A. Childress, BS,Allison M. Davis, MD,Lissa X. Yu, MD

November 11th 2025

GeneDx receives FDA Breakthrough Device Designation for whole genome and exome tests

ByMorgan Ebert, Managing Editor

November 10th 2025

Dale Lee, MD, explains best practices for celiac disease follow-up

ByDale Lee, MD

November 10th 2025

Latest CME

Video

Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)

Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Jay B. Wish, MD

Multimedia

Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies

Glenn M. Chertow, MD, MPH; Anjay Rastogi, MD, PhD

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Multimedia

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Jeffrey A. Sparks, MD, MMSc

Multimedia

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Frank B. Cortazar, MD; Lindsay S. Lally, MD

Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Video

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

Video

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Warning on SimplyThick now includes infants of any age

Newsletter

Related Content

EC prescribing has not changed post Dobbs

FDA, CDC investigating multistate infant botulism outbreak tied to formula

Can you diagnose this 18-year-old with nausea and vomiting?

GeneDx receives FDA Breakthrough Device Designation for whole genome and exome tests

Dale Lee, MD, explains best practices for celiac disease follow-up

Latest CME

Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)

Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Trending on Contemporary Pediatrics

GeneDx receives FDA Breakthrough Device Designation for whole genome and exome tests

Dale Lee, MD, explains best practices for celiac disease follow-up

FDA, CDC investigating multistate infant botulism outbreak tied to formula

Can you diagnose this 18-year-old with nausea and vomiting?

Improved Pediatric AD Clinical Trial Design and Efficacy Outcomes